Rezolute RZLT
NASDAQ RZLT
$4.01 -0.06 (-1.47%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rezolute (RZLT) Gains from Sales and Divestitures (2018 - 2019)

Updated

Rezolute (RZLT) reported Gains from Sales and Divestitures of -$12,000 for FY2019 (year ended Jun 30, 2019), compared with -$663,000 in FY2018.

Analysis

Rezolute (RZLT) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$663,000 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rezolute 386.59 Mn 386.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 11,000.00
Dec 31, 2018 -46,000.00
Sep 30, 2018 23,000.00
Jun 30, 2018 -663,000.00
API Access

Rezolute Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RZLT&period=max&api_key=YOUR_API_KEY